Status:

COMPLETED

Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers

Lead Sponsor:

Bial - Portela C S.A.

Conditions:

Parkinson

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

Single-centre, open-label, randomised, three-part, two-way crossover study in 84 healthy volunteers. In each part, the study consisted of two consecutive single-dose treatment periods separated by a w...

Eligibility Criteria

Inclusion

  • A signed and dated informed consent form before any study-specific screening procedure was performed;
  • Male or female subjects aged 18 to 45 years, inclusive;
  • Body mass index (BMI) between 18 and 30 kg/m2 inclusive;
  • Healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead electrocardiogram (ECG);
  • Negative tests for hepatitis B surface antigen (HBsAg), anti- hepatitis C virus antibodies (HCV Ab) and anti-human immunodeficiency virus antibodies (HIV-1 and HIV-2 Ab) at screening;
  • Clinical laboratory test results clinically acceptable at screening and admission to each treatment period;
  • Negative screen for alcohol and drugs of abuse at screening and admission to each treatment period;
  • Non-smokers or ex-smokers for at least 3 months;
  • Able to participate, and willing to give written informed consent and comply with the study restrictions.
  • If female:
  • She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used an effective non-hormonal method of contraception \[intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical or vault caps) with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he was the sole partner of that subject\] for all the duration of the study;
  • She had a negative serum pregnancy test at screening and a negative urine pregnancy test at admission to each treatment period.

Exclusion

  • Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders, or had a clinically relevant surgical history;
  • Had clinically relevant findings in laboratory tests, particularly any abnormality in the coagulation tests, or any abnormality in the liver function tests;
  • Had a history of relevant atopy or drug hypersensitivity;
  • Had a history of alcoholism and/or drug abuse;
  • Consumed more than 14 units of alcohol per week \[1 unit of alcohol = 280 mL beer (3-4°) = 100 mL wine (10-12°) = 30 mL spirits (40°)\];
  • Had a significant infection or known inflammatory process on screening or admission to each treatment period;
  • Had acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period;
  • Had used medicines within 2 weeks of admission to first period that could affect the safety or other study assessments, in the Investigator's opinion;
  • Had previously received opicapone;
  • Had used any investigational drug or participated in any clinical trial within 90 days prior to screening;
  • Had participated in more than 2 clinical trials within the 12 months prior to screening;
  • Had donated or received any blood or blood products within the 3 months prior to screening;
  • Were vegetarians, vegans or had medical dietary restrictions;
  • Could not communicate reliably with the Investigator;
  • Were unlikely to co-operate with the requirements of the study;
  • Were unwilling or unable to give written informed consent;
  • If female:
  • She was pregnant or breast-feeding.

Key Trial Info

Start Date :

March 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2014

Estimated Enrollment :

85 Patients enrolled

Trial Details

Trial ID

NCT02305277

Start Date

March 1 2014

End Date

June 1 2014

Last Update

March 12 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.